The media swarmed over Illumina's announcement of a system capable of sequencing a human genome for $1,000 in the near future, but when will the company and Thermo Fisher Scientific break that barrier on a routine basis?
After a 2013 of massive improvements to cancer therapy, will 2014 be the year doctors can quickly determine which patients will benefit from which therapies?
Unlocking the "human code" makes possible all manner of changes we might have never considered before. Are we ready for what that might mean?
Teva Pharmaceutical, AMAG Pharmaceuticals, AstraZeneca, and Nektar Therapeutics could loom large in health-care headlines this morning. Here’s why.
The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.
Direct-to-consumer genetic tests took a hit when the Food and Drug Administration told 23andMe to stop marketing its product. However, accepting the arrival of accessible genetic information could ignite growth opportunities for Myriad Genetics, Genomic Health, and Quest Diagnostics.
Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.
Shares of Affymetrix have been on fire over the past year despite lacking any real fundamental fuel. Will this hot stock keep rising, or is it destined to crash and burn?
Diagnostics have been taking off around health care, from fast risers like Illumina to tried-and-true companies like Thermo-Fisher. Don't miss out on this health boom.
An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.